novo nordisk glp-1 drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings Novo Nordisk CEO explains why
Description
No scheduling delays
Growth Opportunity Analysis 2.1.4
Unlike the SUSTAIN-6 study, this study excluded any patients who had pre-existing proliferative diabetic retinopathy (PDR) prior to initiation of tirzepatide and matched patients with their baseline level of DR or DME
Pricing far below market
Its all about the gray market, he says
3,4 Given these trends, there is an urgent need to identify effective strategies to improve glycemic management and mitigate the growing burden of diabetes and obesity worldwide
